The Experts below are selected from a list of 627 Experts worldwide ranked by ideXlab platform
Wolfdieter Heiss - One of the best experts on this subject based on the ideXlab platform.
-
piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients
Stroke, 2000Co-Authors: Josef Kessler, Alexander Thiel, H Karbe, Wolfdieter HeissAbstract:Background and Purpose —In a prospective, double-blind, placebo-controlled study, it was investigated whether piracetam improves language recovery in poststroke aphasia assessed by neuropsychological tests and activation PET measurement of cerebral blood flow. Methods —Twenty-four stroke patients with aphasia were randomly allocated to 2 groups: 12 patients received 2400 mg piracetam twice daily, 12 placebo. Before and at the end of the 6-week treatment period in which both groups received intensive speech therapy, the patients were examined neuropsychologically and studied with H215O PET at rest and during activation with a word-repetition task. Blood flow was analyzed in 14 language-activated brain regions defined on reconstructed surface views from MRI coregistered to the PET images. Results —Before treatment, both groups were comparable with respect to performance in language tasks and to type and severity of aphasia. In the piracetam group, increase of activation effect was significantly higher ( P <0.05) in the left Transverse Temporal Gyrus, left triangular part of inferior frontal Gyrus, and left posterior superior Temporal Gyrus after the treatment period compared with the initial measures. The placebo group showed an increase of activation effect only in the left vocalization area. In the test battery, the piracetam group improved in 6 language functions, the placebo group only in 3 subtests. Conclusions —Piracetam as an adjuvant to speech therapy improves recovery of various language functions, and this effect is accompanied by a significant increase of task-related flow activation in eloquent areas of the left hemisphere.
Zhou Yun - One of the best experts on this subject based on the ideXlab platform.
-
F-AV133 Cerebral VMAT2 Binding in Parkinson’s Disease—A Preliminary Report
Public Library of Science, 2016Co-Authors: Gao Rui, Zhang Guangjian, Chen Xueqi, Yang Aimin, Smith Gwenn, Wong Dean F., Zhou YunAbstract:F-AV133) that is being developed as a biomarker for PD. We test the hypothesis that monoaminergic degeneration was correlated with CSF biomarker levels in untreated PD patients.F-AV133 brain PET, and T1 weighted MRIs. Region of interest (ROI) and voxel-wise Pearson correlation between standardized uptake value ratio (SUVR) and CSF biomarkers were calculated.. In addition, superior frontal Gyrus and Transverse Temporal Gyrus were negatively correlated with CSF p-tau levels.These results suggest that monoaminergic degeneration in PD is correlated with CSF biomarkers associated with cognitive impairment in neurodegenerative diseases including Alzheimer’s disease. The association between loss of dopamine synaptic function and pathologic protein accumulations in PD indicates an important role of CSF biomarkers in PD development
-
CSF Biomarkers and Its Associations with F-18-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report
PLOS ONE, 2016Co-Authors: Gao Rui, Zhang Guangjian, Chen Xueqi, Yang Aimin, Smith Gwenn, Wong Dean F., Zhou YunAbstract:Objective Cerebrospinal fluid (CSF) biomarkers, such as alpha-synuclein (alpha-syn), amyloid beta peptide 1-42 (A beta(1-42)), phosphorylated tau (181P) (p-tau), and total tau (t-tau), have long been associated with the development of Parkinson disease (PD) and other neurodegenerative diseases. In this investigation, we reported the assessment of CSF biomarkers and their correlations with vesicular monoamine transporter 2 (VMAT2) bindings measured with F-18-9-fluoropropyl-(+)-dihydrotetrabenazine (F-18-AV133) that is being developed as a bio-marker for PD. We test the hypothesis that monoaminergic degeneration was correlated with CSF biomarker levels in untreated PD patients. Methods The available online data from the Parkinson's Progression Markers Initiative study (PPMI) project were collected and analyzed, which include demographic information, clinical evaluations, CSF biomarkers (alpha-syn, A beta 1-42, p-tau, and t-tau), F-18-AV133 brain PET, and T1 weighted MRIs. Region of interest (ROI) and voxel-wise Pearson correlation between standardized uptake value ratio (SUVR) and CSF biomarkers were calculated. Results Our major findings are: 1) Compared with controls, CSF alpha-syn and tau levels decreased significantly in PD; 2) alpha-syn was closely correlated with A beta(1-42) and tau in PD, especially in early-onset patients; and 3) hypothesis-driven ROI analysis found a significant negative correlation between CSF A beta(1-42) levels and VMAT2 densities in post cingulate, left caudate,left anterior putamen, and left ventral striatum in PDs. CSF t-tau and p-tau levels were significantly negatively related to VMAT2 SUVRs in substantia nigra and left ventral striatum, respectively. Voxel-wise analysis showed that left caudate, parahippocampal Gyrus, insula and Temporal lobe were negatively correlated with A beta(1-42). In addition, superior frontal Gyrus and Transverse Temporal Gyrus were negatively correlated with CSF p-tau levels. Conclusion These results suggest that monoaminergic degeneration in PD is correlated with CSF biomarkers associated with cognitive impairment in neurodegenerative diseases including Alzheimer's disease. The association between loss of dopamine synaptic function and pathologic protein accumulations in PD indicates an important role of CSF biomarkers in PD development.Michael J. Fox Foundation for Parkinson's Research (MJFF); Industry Scientific Advisory Board (ISAB); Project of Natural Science Foundation Research Project of Shaanxi Province [2016JM8056]; Abbott; Avid; Biogen Idec; Covalence; Elan; GlaxoSmithKline; Lilly; Merck; UCB; F. Hoffman-La Roche Ltd.; GE Healthcare; Genentech; Pfizer Inc.SCI(E)ARTICLEjacky_mg@163.com; yunzhou@jhmi.edu101
Josef Kessler - One of the best experts on this subject based on the ideXlab platform.
-
piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients
Stroke, 2000Co-Authors: Josef Kessler, Alexander Thiel, H Karbe, Wolfdieter HeissAbstract:Background and Purpose —In a prospective, double-blind, placebo-controlled study, it was investigated whether piracetam improves language recovery in poststroke aphasia assessed by neuropsychological tests and activation PET measurement of cerebral blood flow. Methods —Twenty-four stroke patients with aphasia were randomly allocated to 2 groups: 12 patients received 2400 mg piracetam twice daily, 12 placebo. Before and at the end of the 6-week treatment period in which both groups received intensive speech therapy, the patients were examined neuropsychologically and studied with H215O PET at rest and during activation with a word-repetition task. Blood flow was analyzed in 14 language-activated brain regions defined on reconstructed surface views from MRI coregistered to the PET images. Results —Before treatment, both groups were comparable with respect to performance in language tasks and to type and severity of aphasia. In the piracetam group, increase of activation effect was significantly higher ( P <0.05) in the left Transverse Temporal Gyrus, left triangular part of inferior frontal Gyrus, and left posterior superior Temporal Gyrus after the treatment period compared with the initial measures. The placebo group showed an increase of activation effect only in the left vocalization area. In the test battery, the piracetam group improved in 6 language functions, the placebo group only in 3 subtests. Conclusions —Piracetam as an adjuvant to speech therapy improves recovery of various language functions, and this effect is accompanied by a significant increase of task-related flow activation in eloquent areas of the left hemisphere.
Kris Vissers - One of the best experts on this subject based on the ideXlab platform.
-
Alterations in grey matter density and functional connectivity in trigeminal neuropathic pain and trigeminal neuralgia: A systematic review and meta-analysis.
NeuroImage. Clinical, 2019Co-Authors: Dylan J.h.a. Henssen, Jurriaan Dijk, Robin Knepflé, Matthijs Sieffers, Anouk Winter, Kris VissersAbstract:Abstract Background Various studies reported changes in grey matter volumes and modifications in functional connectivity of cortical and subcortical structures in patients suffering from trigeminal neuralgia (TN) and trigeminal neuropathic pain (TNP). This study meta-analyzed the concordant structural and functional changes in foci and provide further understanding of the anatomy and biology of TN/TNP. Methods Relevant articles on magnetic resonance imaging (MRI) and functional MRI in TN/TNP, published before August 2018, were searched for on PubMed and Embase. Following exclusion of unsuitable studies, a meta-analysis was performed using activation likelihood estimation (ALE). Results In total, 322 paper were identified, 11 of which could be included based on the predefined inclusion and exclusion criteria. Eight papers, totaling 279 subjects, discussing structural changes and four papers, totaling 102 subjects, discussing functional changes were included (i.e., one paper investigated both structural and functional alterations). ALE analysis showed that in TN/TNP, grey matter decreases are found in the thalamus, (anterior) cingulate Gyrus, bilateral striatum, the superior-, middle- and Transverse Temporal Gyrus, subcallosal Gyrus, the bilateral insular cortex, the pre- and postcental Gyrus, the middle frontal Gyrus bilaterally and the anterior cerebellar lobe. Grey matter increases were seen in the periaqueductal grey (PAG). Increased resting state functional organization was found within the bilateral middle- and superior frontal gyri, the (posterior) cingulate cortex and the thalamus/pulvinar. Conclusions Structural and functional changes meta-analyzed in this paper may contribute to elucidating the central pathophysiological mechanisms involved in TN/TNP. These results may be used as biomarkers to predict the response to medication and, ideally, in the future to offer personalized treatments.
Gao Rui - One of the best experts on this subject based on the ideXlab platform.
-
F-AV133 Cerebral VMAT2 Binding in Parkinson’s Disease—A Preliminary Report
Public Library of Science, 2016Co-Authors: Gao Rui, Zhang Guangjian, Chen Xueqi, Yang Aimin, Smith Gwenn, Wong Dean F., Zhou YunAbstract:F-AV133) that is being developed as a biomarker for PD. We test the hypothesis that monoaminergic degeneration was correlated with CSF biomarker levels in untreated PD patients.F-AV133 brain PET, and T1 weighted MRIs. Region of interest (ROI) and voxel-wise Pearson correlation between standardized uptake value ratio (SUVR) and CSF biomarkers were calculated.. In addition, superior frontal Gyrus and Transverse Temporal Gyrus were negatively correlated with CSF p-tau levels.These results suggest that monoaminergic degeneration in PD is correlated with CSF biomarkers associated with cognitive impairment in neurodegenerative diseases including Alzheimer’s disease. The association between loss of dopamine synaptic function and pathologic protein accumulations in PD indicates an important role of CSF biomarkers in PD development
-
CSF Biomarkers and Its Associations with F-18-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report
PLOS ONE, 2016Co-Authors: Gao Rui, Zhang Guangjian, Chen Xueqi, Yang Aimin, Smith Gwenn, Wong Dean F., Zhou YunAbstract:Objective Cerebrospinal fluid (CSF) biomarkers, such as alpha-synuclein (alpha-syn), amyloid beta peptide 1-42 (A beta(1-42)), phosphorylated tau (181P) (p-tau), and total tau (t-tau), have long been associated with the development of Parkinson disease (PD) and other neurodegenerative diseases. In this investigation, we reported the assessment of CSF biomarkers and their correlations with vesicular monoamine transporter 2 (VMAT2) bindings measured with F-18-9-fluoropropyl-(+)-dihydrotetrabenazine (F-18-AV133) that is being developed as a bio-marker for PD. We test the hypothesis that monoaminergic degeneration was correlated with CSF biomarker levels in untreated PD patients. Methods The available online data from the Parkinson's Progression Markers Initiative study (PPMI) project were collected and analyzed, which include demographic information, clinical evaluations, CSF biomarkers (alpha-syn, A beta 1-42, p-tau, and t-tau), F-18-AV133 brain PET, and T1 weighted MRIs. Region of interest (ROI) and voxel-wise Pearson correlation between standardized uptake value ratio (SUVR) and CSF biomarkers were calculated. Results Our major findings are: 1) Compared with controls, CSF alpha-syn and tau levels decreased significantly in PD; 2) alpha-syn was closely correlated with A beta(1-42) and tau in PD, especially in early-onset patients; and 3) hypothesis-driven ROI analysis found a significant negative correlation between CSF A beta(1-42) levels and VMAT2 densities in post cingulate, left caudate,left anterior putamen, and left ventral striatum in PDs. CSF t-tau and p-tau levels were significantly negatively related to VMAT2 SUVRs in substantia nigra and left ventral striatum, respectively. Voxel-wise analysis showed that left caudate, parahippocampal Gyrus, insula and Temporal lobe were negatively correlated with A beta(1-42). In addition, superior frontal Gyrus and Transverse Temporal Gyrus were negatively correlated with CSF p-tau levels. Conclusion These results suggest that monoaminergic degeneration in PD is correlated with CSF biomarkers associated with cognitive impairment in neurodegenerative diseases including Alzheimer's disease. The association between loss of dopamine synaptic function and pathologic protein accumulations in PD indicates an important role of CSF biomarkers in PD development.Michael J. Fox Foundation for Parkinson's Research (MJFF); Industry Scientific Advisory Board (ISAB); Project of Natural Science Foundation Research Project of Shaanxi Province [2016JM8056]; Abbott; Avid; Biogen Idec; Covalence; Elan; GlaxoSmithKline; Lilly; Merck; UCB; F. Hoffman-La Roche Ltd.; GE Healthcare; Genentech; Pfizer Inc.SCI(E)ARTICLEjacky_mg@163.com; yunzhou@jhmi.edu101
